<DOC>
	<DOCNO>NCT02447939</DOCNO>
	<brief_summary>Present clinical study conduct China evaluate pharmacokinetics ( PK ) single repeat oral dos dabrafenib alone dabrafenib trametinib combination , safety profile clinical activity dabrafenib combination trametinib Chinese melanoma subject BRAF V600E/K mutation . Approximately 20 evaluable subject enrol study , , first 10 subject enrol cohort A ( Part I II ) remain 10 subject enrol cohort B . Subjects cohort A ( Part I ) receive dabrafenib 150 mg twice daily ( BID ) subject cohort A ( Part II ) Cohort B receive combination dabrafenib 150 mg BID trametinib 2 mg daily ( QD ) . Study treatment continue disease progression , death unacceptable toxicity . After disease progression , enrol subject follow overall survival . The study complete subject die survive subject least 5 year follow-up , whichever occurs first .</brief_summary>
	<brief_title>Pharmacokinetics Repeat Oral Doses Dabrafenib Combination Dabrafenib Trametinib Chinese Subjects With Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Provided sign write informed consent . Males females &gt; =18 year age . Histologically confirm cutaneous melanoma either Stage IIIC ( unresectable ) Stage IV ( metastatic ) , BRAF V600E/K mutationpositive designate qualified laboratory study . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate baseline organ function define : Absolute neutrophil count ( ANC ) : &gt; =1,200 /microliter ( uL ) ; Hemoglobin : &gt; =9 gram ( g ) /deciliter ( dL ) ; Platelets : &gt; =100,000 /uL ; Prothrombin time/ International normalization ratio activate partial thromboplastin time : &lt; =1.3 x Upper Limit Normal ( ULN ) ; Total bilirubin : &lt; =1.5 x ULN ; Aspartate aminotransferase Alanine aminotransferase : &lt; =2.5 x ULN ; Calculated creatinine clearance ( Calculate creatinine clearance use standard CockcroftGault formula ) : &gt; =50 milliliter ( mL ) / minute ( min ) 24hour urine creatinine clearance &gt; =50 mL/min ; Left ventricular Ejection fraction ( LVEF ) : &gt; /= 50 % LVEF case establish Lower limit normal ( LLN ) give institution . Prior treatment BRAF inhibitor MEK inhibitor Pregnant Lactating female . History another malignancy . Subjects previous malignancy confirm activate RAS mutation time eligible . Note : Prospective RAS testing require . However , result previous RAS test know , must use assess eligibility . Exception : Subjects diseasefree 5 year ( except confirm activate RAS mutation ) , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . Brain metastasis exclude unless : All know lesion definitively treat surgery stereotactic surgery ( wholebrain radiation may give adjuvant treatment ) , OR Brain lesion ( ) , still present , must confirm stable ( i.e. , increase lesion size ) &gt; =12 week prior enrollment ( stability must confirm two consecutive magnetic resonance image ( MRI ) compute tomography ( CT ) scan contrast , separate &gt; 6 week AND Asymptomatic corticosteroid requirement &gt; =4 week prior enrollment , AND No enzyme induce anticonvulsant &gt; =2 week prior enrollment . In addition , subject brain metastasis currently evidence disease ( NED ) , NED &gt; =12 week require must confirm two consecutive scan , separate &gt; =6 week , prior enrollment . Any serious and/or unstable preexist medical disorder ( aside malignancy exception ) , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent compliance study procedure . Any major surgery , extensive radiotherapy , chemotherapy delay toxicity , biologic therapy , immunotherapy within 21 day prior enrolment and/or daily weekly chemotherapy without potential delayed toxicity within 14 day prior enrolment . Any prohibited medication ( ) . Administration investigational study treatment within 30 day 5 halflives , whichever longer , precede first dose study treatment ( ) study . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study treatment , excipients , and/or dimethyl sulfoxide ( DMSO ) . A history evidence cardiovascular risk include follow : Current LVEF &lt; Institutional LLN ; QTc interval correct heart rate &gt; =480 millisecond ( msec ) ( use Bazett 's formula ) ; history evidence current clinically significant uncontrolled arrhythmia ; Exception : Subjects atrial fibrillation control &gt; 30 day prior enrollment eligible ; history ( within 6 month prior enrollment ) acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty ; history evidence current &gt; =Class II congestive heart failure define New York Heart Association ( NYHA ) guideline ; treatment refractory hypertension define blood pressure systolic &gt; 140 millimeter mercury ( mmHg ) and/or diastolic &gt; 90 mm Hg control antihypertensive therapy ; subject intracardiac defibrillator ; abnormal cardiac valve morphology ( &gt; =Grade 2 ) document echocardiogram ( subject grade 1 abnormality [ i.e. , mild regurgitation/stenosis ] enter study ) . Subjects moderate valvular thickening enter study . Uncorrectable electrolyte abnormality ( e.g . hypokalaemia , hypomagnesaemia , hypocalcaemia determine blood chemistry ) , long QT syndrome take medicinal product know prolong QT interval . A history retinal vein occlusion ( RVO ) History interstitial lung disease pneumonitis . History HIV infection . History Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection . Subjects laboratory evidence clear HBV and/or HCV permit , define HBs antigen negative HBV Deoxyribonucleic acid ( DNA ) negative ; HCV antibody negative .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>trametinib</keyword>
	<keyword>cutaneous melanoma</keyword>
	<keyword>dabrafenib</keyword>
	<keyword>safety</keyword>
</DOC>